Under the agreement, the University will provide OpenBench with promising drug candidates and OpenBench will conduct a virtual screening. The company will be paid upon delivering the leads to the University, according to a Nov. 9 OpenBench news release.
“As Carolina researchers develop critical therapeutics for cancer and other diseases, we look for new and innovative ways to move potential treatments to market faster, so that patients can benefit sooner,” UNC Chief Innovation Officer Michelle Bolas said. “We are delighted to team with OpenBench to unlock the commercial and therapeutic potential of emerging scientific discoveries.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
